With over 0.1 million Cardiol Therapeutics Inc. (CRDL) shares trading Tuesday and a closing price of $0.71 on the day, the dollar volume was approximately $72586.84999999999. The shares have shown a negative half year performance of -45.96% and its price on 01/24/23 gained nearly 3.94%. Currently, there are 62.34M common shares owned by the public and among those 61.11M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 3 analysts who have offered their price forecasts for CRDL have a consensus price objective of $3.53. The analysts have set the share’s price value over the next 12 months at a high of $5.00 and a low of $2.24. But an upside of 85.8% will see the stock hit the forecast high price target while median target price for the stock is $3.34.
The top 3 mutual fund holders in Cardiol Therapeutics Inc. are Cannabis ETF, Global X Cannabis ETF, and AdvisorShares Trust – Pure Cannab. Cannabis ETF owns 1.9 million shares of the company’s stock, all valued at over $0.97 million. AdvisorShares Trust – Pure Cannab now owns shares totaling to 1.76% of the shares outstanding.
Shares of Cardiol Therapeutics Inc. (NASDAQ: CRDL) opened at $0.70, up $0.02 from a prior closing price of $0.68. However, the script later moved the day high at 0.7366, up 3.94%. The company’s stock has a 5-day price change of -8.30% and 31.13% over the past three months. CRDL shares are trading 38.82% year to date (YTD), with the 12-month market performance down to -61.10% lower. It has a 12-month low price of $0.47 and touched a high of $2.08 over the same period. CRDL has an average intraday trading volume of 141.85K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 12.68%, 18.95%, and -32.37% respectively.
Institutional ownership of Cardiol Therapeutics Inc. (NASDAQ: CRDL) shares accounts for 13.20% of the company’s 62.34M shares outstanding. Mutual fund holders own –, while other institutional holders and individual stakeholders account for — and — respectively.
It has a market capitalization of $60.28M and a beta (3y monthly) value of 0.76. The earnings-per-share (ttm) stands at -$0.49. The company has a debt-to-equity ratio at 0.00. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.72% over the week and 9.17% over the month.
Earnings per share for the fiscal year are expected to decrease by -5.90%, and 5.10% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 3 brokerage firm advisors rate Cardiol Therapeutics Inc. (CRDL) as a “Moderate Buy” at a consensus score of 2.00. Specifically, 3 Wall Street analysts polled rate the stock as a buy, while 0 of the 3 advise that investors “hold,” and 0 rated it as a “Sell.”